Nano Approaches to Modulate Host Cell Response for Cancer Therapy

调节宿主细胞反应以进行癌症治疗的纳米方法

基本信息

  • 批准号:
    8960618
  • 负责人:
  • 金额:
    $ 226.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-09-01 至 2020-07-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Host response targeting of both immune and stromal components, represents a game changing opportunity to overcome cancer through the body's built in defense mechanisms. Our focus in this application is to exploit the host response through nano approaches for cancer disease management and treatment. We propose developing targeted methods for the delivery of biologics and, immunologic- modifiers and chemotherapies against melanoma and non-small cell lung cancers (NSCLC), utilizing innovative nanotechnologies developed here at UNC-Chapel Hill. We have proposed four projects in this proposal. The projects revolve around the central theme of exploiting the host response against tumors with an emphasis on the immune response. Project 1 is the designated basic science project since novel polymetformin nanoparticles are being proposed for more efficient and effective delivery of siRNA, which is a critical challenge for drug delivery The project targets Vemurafenib resistant melanoma, and emphasizes direct suppression of drug resistance that is coupled with a new vaccine approach. Project 2 evaluates ways to enhance the anti-tumor immune response through novel delivery of antigens via Particle Replication in Non-wetting Templates (PRINT(r)) nanoparticles. Unique adjuvants, such as Pathogen-associated Molecular Patterns, are being explored as well as the active suppression of blockers of host immunity in melanoma. Project 3 takes advantage of the biology of antigen release and the abscopal effect post irradiation through specifically designed nanoparticles to enhance antigen capture and the immune response to both primary tumors and metastases in melanoma. Project 4 uses polymeric micelles with high capacity loading to deliver therapeutics targeted to the tumor microenvironment as well as tumor cells in NSCLC. In summary, our Carolina CCNE is focused on improving cancer disease control and management to enhance treatment options for patients by the use of novel nanoparticles used in innovative ways that should have impact far beyond the specific disease conditions that are being studied.
 描述(由申请人提供):免疫和基质成分的宿主反应靶向,代表着通过身体内置的防御机制战胜癌症的一个改变游戏规则的机会。我们在这项应用中的重点是通过纳米方法利用宿主的反应来管理和治疗癌症。我们建议开发有针对性的方法,利用北卡罗来纳大学教堂山分校开发的创新纳米技术,提供针对黑色素瘤和非小细胞肺癌(NSCLC)的生物制剂、免疫调节剂和化疗药物。在这份提案中,我们提出了四个项目。这些项目围绕着一个中心主题,即利用宿主对肿瘤的反应,重点是免疫反应。项目1是指定的基础科学项目,因为新的聚二甲双胍纳米颗粒被提出用于更高效和有效地传递siRNA,这是药物传递的关键挑战。该项目针对Vemurafenib耐药黑色素瘤,强调直接抑制耐药性,并结合新的疫苗方法。项目2评估了通过在非润湿模板(Print(R))纳米颗粒中进行粒子复制来新型抗原传递来增强抗肿瘤免疫反应的方法。人们正在探索独特的佐剂,如病原体相关的分子模式,以及在黑色素瘤中主动抑制宿主免疫阻滞剂。项目3利用辐射后抗原释放的生物学和非局域效应,通过专门设计的纳米颗粒来增强抗原捕获和对黑色素瘤原发肿瘤和转移的免疫反应。项目4使用高容量负载的聚合物胶束来输送针对非小细胞肺癌肿瘤微环境和肿瘤细胞的治疗药物。总而言之,我们卡罗莱纳州的CCNE专注于改善癌症疾病的控制和管理,通过使用以创新方式使用的新型纳米颗粒来增强患者的治疗选择,这些纳米颗粒的影响应该远远超出正在研究的特定疾病条件。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Leaf Huang其他文献

Leaf Huang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Leaf Huang', 18)}}的其他基金

Project 1: Nanotherapies for Vemurafenib Resistant Melanoma
项目 1:维莫非尼耐药黑色素瘤的纳米疗法
  • 批准号:
    8960620
  • 财政年份:
    2015
  • 资助金额:
    $ 226.19万
  • 项目类别:
Hepatic Non-viral Gene Therapy
肝脏非病毒基因治疗
  • 批准号:
    8731891
  • 财政年份:
    2013
  • 资助金额:
    $ 226.19万
  • 项目类别:
Hepatic Non-viral Gene Therapy
肝脏非病毒基因治疗
  • 批准号:
    8613538
  • 财政年份:
    2013
  • 资助金额:
    $ 226.19万
  • 项目类别:
Therapeutic Targeting of the Ras Pathway By Nanoparticle Delivery of siRNA
通过 siRNA 纳米颗粒递送来治疗 Ras 通路
  • 批准号:
    8540374
  • 财政年份:
    2013
  • 资助金额:
    $ 226.19万
  • 项目类别:
Hepatic Non-viral Gene Therapy
肝脏非病毒基因治疗
  • 批准号:
    8882415
  • 财政年份:
    2013
  • 资助金额:
    $ 226.19万
  • 项目类别:
Nanocrystals for the Treatment of Multidrug Resistance in Cancer
用于治疗癌症多药耐药性的纳米晶体
  • 批准号:
    8680176
  • 财政年份:
    2011
  • 资助金额:
    $ 226.19万
  • 项目类别:
Therapeutic Targeting of the Ras Pathway By Nanoparticle Delivery of siRNA
通过 siRNA 纳米颗粒递送来治疗 Ras 通路
  • 批准号:
    7982953
  • 财政年份:
    2010
  • 资助金额:
    $ 226.19万
  • 项目类别:
Novel nanoparticles for siRNA delivery
用于 siRNA 递送的新型纳米颗粒
  • 批准号:
    8212466
  • 财政年份:
    2010
  • 资助金额:
    $ 226.19万
  • 项目类别:
Novel nanoparticles for siRNA delivery
用于 siRNA 递送的新型纳米粒子
  • 批准号:
    8606435
  • 财政年份:
    2010
  • 资助金额:
    $ 226.19万
  • 项目类别:
Novel nanoparticles for siRNA delivery
用于 siRNA 递送的新型纳米颗粒
  • 批准号:
    8053486
  • 财政年份:
    2010
  • 资助金额:
    $ 226.19万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 226.19万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 226.19万
  • 项目类别:
    Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 226.19万
  • 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 226.19万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 226.19万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 226.19万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 226.19万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 226.19万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 226.19万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 226.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了